We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Tests for Smell Loss May Detect Alzheimer’s and PD

By LabMedica International staff writers
Posted on 16 Oct 2017
In a new approach to testing for olfaction dysfunction, researchers have developed “white smells,” mixtures of several odor molecules, which help reduce test bias and patient subjectivity, thus also creating a more globally applicable testing format. More...
They suggest that these tests could also aid in earlier detection of neurological disorders that have been associated with olfaction problems.

The sense of smell is often taken for granted, until it malfunctions. Researchers at Rockefeller University (New York City, NY, USA) are developing a new type of test to help improve diagnosis of smell disorders and of associated diseases that can be detected with smell tests.

“People have their vision and hearing tested throughout their lives, but smell testing is exceedingly rare,” said Leslie Vosshall, who professor at Rockefeller U. and a Howard Hughes Medical Institute investigator, and who developed the new test format with Julien Hsieh, a Rockefeller clinical scholar who’s now a resident at the Geneva University Hospitals (Switzerland), and colleagues.

One problem with current tests for smell limitations is that they rely on a patient’s ability to detect and identify (name) single types of odor molecules, such as rose-scented phenylethyl alcohol. However, the ability to detect odors and to recognize them can vary greatly between people. Someone with an otherwise normal sense of smell may not be able to detect the rose molecule, while another person who can smell roses but is from an area where these flowers are scarce may struggle to put a name to the scent. In either case, there is the potential for misdiagnosis, particularly when testing across different populations and regions.

The researchers set out to eliminate these potential biases with the help of “white smells,” named based on conceptual similarity to “white light” as combination of wavelengths of light, and “white noise” as combination of many frequencies of sound. They prepared “white smells” by mixing many odors together to produce something unfamiliar, from assortments of 30 different odor molecules.

Their two new tests ask patients to distinguish white smells with overlapping ingredients and to detect white smells at increasingly lower concentrations. If a person is unable to detect a single component of the test scent, this has little effect on the result. Furthermore, test-takers do not need to identify the odor at all: “[The tests] focus on the problem of smell itself, because they don’t force people to match smells to words,” said Prof. Vosshall.

In clinical trials conducted at Rockefeller University Hospital (NY, USA) and Taichung Veterans General Hospital (Taiwan), the new tests detected smell loss more reliably than conventional options. The results open up the possibility of a better means to detect smell loss, and even to aid in detection of Alzheimer’s and Parkinson’s diseases by using “changes in the sense of smell, along with other biomarkers, to identify underlying causes of these neurological disorders very early, and so potentially improve treatment,” said Dr. Hsieh.

The study, by Hsieha JW et al, was published October 10, 2017, in the journal Proceedings of the National Academy of Sciences (PNAS).

Related Links:
Rockefeller University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Automated Immunoassay Analyzer
SuperFlex™
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: The model combines digitized tumor histopathology, clinical variables, and a 42-gene molecular panel using AI to generate a unified recurrence risk prediction (Image Credit: Shutterstock)

Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing

Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.